Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Oncology in Clinical Practice
MENU
Shortcuts Submit an article Author Guidelines Ahead Of Print Reviewers 2020 Professor Krzysztof Krzemieniecki Award

open access

Vol 14, No 6 (2018)
Review paper
Published online: 2019-03-15
View PDF Download PDF file
Get Citation

Clear cell sarcoma

Anna M. Czarnecka, Paweł Sobczuk, Marcin Zdzienicki, Mateusz Spałek, Monika Dudzisz-Śledź, Piotr Rutkowski
DOI: 10.5603/OCP.2018.0049
·
Oncol Clin Pract 2018;14(6):354-363.

open access

Vol 14, No 6 (2018)
REVIEW ARTICLES
Published online: 2019-03-15

Abstract

Clear cell sarcoma (CCS), also referred as to melanoma of soft tissues, is a rare malignant tumour of soft tissues. This tumour harbors the characteristic features of soft tissue sarcoma (STS) and is a slowly growing, painless tumour, which then acquires an aggressive course. CCS is characterized by a translocation t(12; 22)(q13; q12), which in addition to the diagnostic implications may be important for targeted treatment in the future. CCS occurs mainly on the limbs, most often shin (in feet and ankle area) in the tendons and aponeurosis, often at a young age. CCS is characterized by high potential to develop metastases in regional lymph nodes (about 30% of cases). In the diagnostic process one should consider performing a sentinel node biopsy with possible subsequent radical lymphadenectomy in the case of metastases detection. Treatment of localized disease is limited to radical local excision with complementary radiotherapy. Due to the resistance to classical chemotherapy and the presence of characteristic molecular abnormalities, trials of molecular targeted therapies in this group of cancers are ongoing. In clinical trials, MET inhibitors, tyrosine kinase inhibitors (TKI) — sunitinib and pazopanib were evaluated. CCS was also one of the subtypes of tumours evaluated in the CREATE clinical trial with crizotinib.

Abstract

Clear cell sarcoma (CCS), also referred as to melanoma of soft tissues, is a rare malignant tumour of soft tissues. This tumour harbors the characteristic features of soft tissue sarcoma (STS) and is a slowly growing, painless tumour, which then acquires an aggressive course. CCS is characterized by a translocation t(12; 22)(q13; q12), which in addition to the diagnostic implications may be important for targeted treatment in the future. CCS occurs mainly on the limbs, most often shin (in feet and ankle area) in the tendons and aponeurosis, often at a young age. CCS is characterized by high potential to develop metastases in regional lymph nodes (about 30% of cases). In the diagnostic process one should consider performing a sentinel node biopsy with possible subsequent radical lymphadenectomy in the case of metastases detection. Treatment of localized disease is limited to radical local excision with complementary radiotherapy. Due to the resistance to classical chemotherapy and the presence of characteristic molecular abnormalities, trials of molecular targeted therapies in this group of cancers are ongoing. In clinical trials, MET inhibitors, tyrosine kinase inhibitors (TKI) — sunitinib and pazopanib were evaluated. CCS was also one of the subtypes of tumours evaluated in the CREATE clinical trial with crizotinib.

Full Text:

View PDF Download PDF file
Get Citation

Keywords

clear cell sarcoma; crizotinib; sentinel node biopsy; sarcoma; translocation

About this article
Title

Clear cell sarcoma

Journal

Oncology in Clinical Practice

Issue

Vol 14, No 6 (2018)

Article type

Review paper

Pages

354-363

Published online

2019-03-15

DOI

10.5603/OCP.2018.0049

Bibliographic record

Oncol Clin Pract 2018;14(6):354-363.

Keywords

clear cell sarcoma
crizotinib
sentinel node biopsy
sarcoma
translocation

Authors

Anna M. Czarnecka
Paweł Sobczuk
Marcin Zdzienicki
Mateusz Spałek
Monika Dudzisz-Śledź
Piotr Rutkowski

References (77)
  1. Cornillie J, van Cann T, Wozniak A, et al. Biology and management of clear cell sarcoma: state of the art and future perspectives. Expert Rev Anticancer Ther. 2016; 16(8): 839–845.
    CrossRefPubMed
  2. ENZINGER FM. Clear-cell sarcoma of tendons and aponeuroses. An analysis of 21 cases. Cancer. 1965; 18: 1163–1174, doi: 10.1002/1097-0142(196509)18:9<1163::aid-cncr2820180916>3.0.co;2-0.
    PubMed
  3. Chung EB, Enzinger FM. Malignant melanoma of soft parts. A reassessment of clear cell sarcoma. Am J Surg Pathol. 1983; 7(5): 405–413.
    CrossRefPubMed
  4. Lucas DR, Nascimento AG, Sim FH. Clear cell sarcoma of soft tissues. Mayo Clinic experience with 35 cases. Am J Surg Pathol. 1992; 16(12): 1197–1204.
    CrossRefPubMed
  5. Clark MA, Johnson MB, Thway K, et al. Clear cell sarcoma (melanoma of soft parts): The Royal Marsden Hospital experience. Eur J Surg Oncol. 2008; 34(7): 800–804.
    CrossRefPubMed
  6. Malchau SS, Hayden J, Hornicek F, et al. Clear cell sarcoma of soft tissues. J Surg Oncol. 2007; 95(6): 519–522.
    CrossRefPubMed
  7. Bianchi G, Charoenlap C, Cocchi S, et al. Clear cell sarcoma of soft tissue: a retrospective review and analysis of 31 cases treated at Istituto Ortopedico Rizzoli. Eur J Surg Oncol. 2014; 40(5): 505–510.
    CrossRefPubMed
  8. Kawai A, Nakayama R, Matsumine A, et al. Clear cell sarcoma of tendons and aponeuroses: an analysis of 75 cases. J Clin Oncol. 2006; 24(Suppl 18): 9572–9572.
    PubMed
  9. Bali A, Roy M, Chikkannaiah P, et al. Cutaneous clear cell sarcoma: a rare aggressive tumor with potential diagnostic challenge. J Lab Physicians. 2012; 4(1): 53–55.
    CrossRefPubMed
  10. Hantschke M, Mentzel T, Rütten A, et al. Cutaneous clear cell sarcoma: a clinicopathologic, immunohistochemical, and molecular analysis of 12 cases emphasizing its distinction from dermal melanoma. Am J Surg Pathol. 2010; 34(2): 216–222.
    CrossRef
  11. Jin L, Sui Y, Zhu H, et al. Primary mediastinal clear cell sarcoma: a case report and review of the literature. Diagn Pathol. 2017; 12(1): 5.
    CrossRefPubMed
  12. Abdollahi A, Khatami F, Tavangar SM. Clear cell sarcoma: a case report and review of literature. Int J Hematol Oncol Stem Cell Res. 2018; 12(1): 65–68.
    PubMed
  13. Kawai A, Hosono A, Nakayama R, et al. Japanese Musculoskeletal Oncology Group. Clear cell sarcoma of tendons and aponeuroses: a study of 75 patients. Cancer. 2007; 109(1): 109–116.
    CrossRefPubMed
  14. Gonzaga MI, Grant L, Curtin C, et al. The epidemiology and survivorship of clear cell sarcoma: a National Cancer Database (NCDB) review. J Cancer Res Clin Oncol. 2018; 144(9): 1711–1716.
    CrossRefPubMed
  15. Hocar O, Le Cesne A, Berissi S, et al. Clear cell sarcoma (malignant melanoma) of soft parts: a clinicopathologic study of 52 cases. Dermatol Res Pract. 2012; 2012: 984096.
    CrossRefPubMed
  16. Yang XL, Lu SJ, Xue J, et al. Clear cell sarcoma of the right lumbar region: a case report and review of the literature. Oncol Lett. 2014; 8(4): 1625–1627.
    CrossRefPubMed
  17. Hisaoka M, Ishida T, Kuo TT, et al. Clear cell sarcoma of soft tissue: a clinicopathologic, immunohistochemical, and molecular analysis of 33 cases. Am J Surg Pathol. 2008; 32(3): 452–460.
    CrossRefPubMed
  18. Auerbach A, Cassarino DS. Clear cell tumors of soft tissue. Surg Pathol Clin. 2011; 4(3): 783–798.
    CrossRefPubMed
  19. Yang L, Chen Y, Cui T, et al. Identification of biomarkers to distinguish clear cell sarcoma from malignant melanoma. Hum Pathol. 2012; 43(9): 1463–1470.
    CrossRefPubMed
  20. Patel RM, Downs-Kelly E, Weiss SW, et al. Dual-color, break-apart fluorescence in situ hybridization for EWS gene rearrangement distinguishes clear cell sarcoma of soft tissue from malignant melanoma. Mod Pathol. 2005; 18(12): 1585–1590.
    CrossRefPubMed
  21. Meis-Kindblom JM. Clear cell sarcoma of tendons and aponeuroses: a historical perspective and tribute to the man behind the entity. Adv Anat Pathol. 2006; 13(6): 286–292.
    CrossRefPubMed
  22. Mrózek K, Karakousis CP, Perez-Mesa C, et al. Translocation t(12;22)(q13;q12.2-12.3) in a clear cell sarcoma of tendons and aponeuroses. Gene Chromosome Canc. 1993; 6(4): 249–252.
    CrossRefPubMed
  23. Reeves BR, Fletcher CD, Gusterson BA. Translocation t(12;22)(q13;q13) is a nonrandom rearrangement in clear cell sarcoma. Cancer Genet Cytogenet. 1992; 64(2): 101–103.
    PubMed
  24. Davis IJ, Kim JJ, Ozsolak F, et al. Oncogenic MITF dysregulation in clear cell sarcoma: defining the MiT family of human cancers. Cancer Cell. 2006; 9(6): 473–484.
    CrossRefPubMed
  25. Panagopoulos I, Mertens F, Dębiec-Rychter M, et al. Molecular genetic characterization of the EWS/ATF1 fusion gene in clear cell sarcoma of tendons and aponeuroses. Int J Cancer. 2002; 99(4): 560–567.
    CrossRefPubMed
  26. Fisher C. The diversity of soft tissue tumours with EWSR1 gene rearrangements: a review. Histopathology. 2014; 64(1): 134–150.
    CrossRefPubMed
  27. Rossi S, Szuhai K, Ijszenga M, et al. EWSR1-CREB1 and EWSR1-ATF1 fusion genes in angiomatoid fibrous histiocytoma. Clin Cancer Res. 2007; 13(24): 7322–7328.
    CrossRefPubMed
  28. Mavrogenis Af, Bianchi G, Stavropoulos Na, et al. Clinicopathological features, diagnosis and treatment of clear cell sarcoma/melanoma of soft parts. Hippokratia. 2013; 17(4): 298–302.
    PubMed
  29. Davis IJ, McFadden AW, Zhang Y, et al. Identification of the receptor tyrosine kinase c-Met and its ligand, hepatocyte growth factor, as therapeutic targets in clear cell sarcoma. Cancer Res. 2010; 70(2): 639–645.
    CrossRefPubMed
  30. Negri T, Brich S, Conca E, et al. Receptor tyrosine kinase pathway analysis sheds light on similarities between clear-cell sarcoma and metastatic melanoma. Gene Chromosome Canc. 2012; 51(2): 111–126.
    CrossRefPubMed
  31. Pearl ML, Inagami M, McCauley DL, et al. Mesna, doxorubicin, ifosfamide, and dacarbazine (MAID) chemotherapy for gynecological sarcomas. Int J Gynecol Cancer. 2002; 12(6): 745–748.
    PubMed
  32. Mariappan D, Shashikala Dr. Molecular genetics, diagnosis and management of clear cell sarcoma of hand. IOSR-JDMS. 2016; 15(07): 15–22.
    CrossRef
  33. Deyrup AT. Paraganglioma-like dermal melanocytic tumor: a unique entity distinct from cellular blue nevus, clear cell sarcoma, and cutaneous melanoma. Am J Surg Pathol. 2004; 28(12): 1579–1586.
    PubMed
  34. Thyvalappil A, Sudhamani B, Kizhakkethara G, et al. Paraganglioma-like dermal melanocytic tumor. Indian J Dermatol. 2015; 60(1): 80–81.
    CrossRefPubMed
  35. Folpe AL, Goodman ZD, Ishak KG, et al. Clear cell myomelanocytic tumor of the falciform ligament/ligamentum teres: a novel member of the perivascular epithelioid clear cell family of tumors with a predilection for children and young adults. Am J Surg Pathol. 2000; 24(9): 1239–1246.
    PubMed
  36. Beuckeleer LHDe, Schepper AMDe, Vandevenne JE, et al. MR imaging of clear cell sarcoma (malignant melanoma of the soft parts): a multicenter correlative MRI-pathology study of 21 cases and literature review. Skeletal Radiology. 2000; 29(4): 187–195.
    CrossRef
  37. Tordjman M, Dubois M, de Malherbe M, et al. Clear cell sarcoma of the tongue on MRI and PET/CT. Clin Nucl Med. 2018; 43(4): e118–e121.
    CrossRefPubMed
  38. Nguyen BaD, Roarke MC, Ram PC. PET monitoring of clear cell sarcoma of tendons and aponeuroses. Clin Nucl Med. 2007; 32(5): 415–417.
    CrossRefPubMed
  39. Hocar O, Cesne ALe, Terrier P, et al. Clear cell sarcoma (CCS) or malignant melanoma of soft parts: a retrospective clinicopathologic study of 52 cases. J Oncol. 2008; 26(Suppl 15): 10576–10576.
    CrossRefPubMed
  40. Pasquali S, Gronchi A. Neoadjuvant chemotherapy in soft tissue sarcomas: latest evidence and clinical implications. Ther Adv Med Oncol. 2017; 9(6): 415–429.
    CrossRefPubMed
  41. Boglione A, Bergnolo P, Canton OD, et al. P04Systemic therapy in clear cell sarcoma (CCS). Annals of Oncology. 2016; 27(Suppl 4): 99.
    CrossRef
  42. Jones RL, Constantinidou A, Thway K, et al. Chemotherapy in clear cell sarcoma. Med Oncol. 2011; 28(3): 859–863.
    CrossRefPubMed
  43. Yalcin S, Barista I, Tekuzman G, et al. Dramatic response to ifosfamide, mesna and doxorubicin chemotherapy regimen in an adult with clear cell sarcoma of the kidney. J Urol. 1996; 155(6): 2024.
    CrossRef
  44. Tazzari M, Palassini E, Vergani B, et al. Melan-A/MART-1 immunity in a EWS-ATF1 translocated clear cell sarcoma patient treated with sunitinib: a case report. BMC Cancer. 2015; 15: 58.
    CrossRefPubMed
  45. Juel J, Ibrahim RM. A case of clear cell sarcoma-A rare malignancy. Int J Surg Case Rep. 2017; 36: 151–154.
    CrossRefPubMed
  46. Abdellah A, Soufiane B, Amine B, et al. Clear cell sarcoma of tendons and aponeuroses of the parapharyngeal space: an unusual localization of a rare tumor (a case report and review of the literature). Pan Afr Med J. 2014; 19: 147.
    CrossRefPubMed
  47. van Akkooi ACJ, Verhoef C, van Geel AN, et al. Sentinel node biopsy for clear cell sarcoma. Eur J Surg Oncol. 2006; 32(9): 996–999.
    CrossRefPubMed
  48. Andreou D, Boldt H, Werner M, et al. Sentinel node biopsy in soft tissue sarcoma subtypes with a high propensity for regional lymphatic spread — results of a large prospective trial. Ann Oncol. 2013; 24(5): 1400–1405.
    CrossRefPubMed
  49. Al-Refaie WB, Ali MW, Chu DZ, et al. Clear cell sarcoma in the era of sentinel lymph node mapping. J Surg Oncol. 2004; 87(3): 126–129.
    CrossRefPubMed
  50. Tong TR, Chow Tc, Chan OWh, et al. Clear-cell sarcoma diagnosis by fine-needle aspiration: cytologic, histologic, and ultrastructural features; potential pitfalls; and literature review. Diagn Cytopathol. 2002; 26(3): 174–180.
    PubMed
  51. Ferrari A, Casanova M, Bisogno G, et al. Clear cell sarcoma of tendons and aponeuroses in pediatric patients: a report from the Italian and German Soft Tissue Sarcoma Cooperative Group. Cancer. 2002; 94(12): 3269–3276.
    CrossRefPubMed
  52. Picciotto F, Zaccagna A, Derosa G, et al. Clear cell sarcoma (malignant melanoma of soft parts) and sentinel lymph node biopsy. Eur J Dermatol. 2005; 15(1): 46–48.
    PubMed
  53. Nishida Y, Yamada Y, Tsukushi S, et al. Sentinel lymph node biopsy reveals a positive popliteal node in clear cell sarcoma. Anticancer Res. 2005; 25(6C): 4413–4416.
    PubMed
  54. Fantini F, Monari P, Bassissi S, et al. Sentinel lymph node biopsy in clear cell sarcoma. J Eur Acad Dermatol Venereol. 2007; 21(9): 1271–1272.
    CrossRefPubMed
  55. Deenik W, Mooi WJ, Rutgers EJ, et al. Clear cell sarcoma (malignant melanoma) of soft parts: A clinicopathologic study of 30 cases. Cancer. 1999; 86(6): 969–975, doi: 10.1002/(sici)1097-0142(19990915)86:6<969::aid-cncr11>3.3.co;2-q.
    PubMed
  56. Constantinidou A, Jones RL, Al-Muderis O, et al. Systemic therapy in clear cell sarcoma. J Clin Oncol. 2010; 28(Suppl 15): 10098–10098.
    CrossRef
  57. Stacchiotti S, Palassini E, Negri T, et al. Clear cell sarcoma (CCR): Clinical behavior and response to chemotherapy. J Clin Oncol. 2010; 28(Suppl 15): 10096–10096.
    CrossRef
  58. Fujimoto M, Hiraga M, Kiyosawa T, et al. Complete remission of metastatic clear cell sarcoma with DAV chemotherapy. Clin Exp Dermatol. 2003; 28(1): 22–24.
    CrossRefPubMed
  59. Tran H, Asfour V, Chang C, et al. Clear cell sarcoma arising from the iliac wing: case report. I J Oncol. 2009; 6(2): 1–5.
    CrossRef
  60. Kumar Kushwaha A, Soni S. Metastatic Clear Cell Sarcoma Role of Temazolamide. Journal of Dental and Medical Sciences 2016. OSR-JDMS. 2016; 15(12, ver. II): 8–9.
    CrossRef
  61. Katz D, Palmerini E, Pollack SM. More than 50 subtypes of soft tissue sarcoma: paving the path for histology-driven treatments. Am Soc Clin Oncol Educ Book. 2018(38): 925–938.
    CrossRefPubMed
  62. Goldberg J, Demetri GD, Choy E, et al. Preliminary results from a phase II study of ARQ 197 in patients with microphthalmia transcription factor family (MiT)-associated tumors. Journal of Clinical Oncology, 2009. J Clin Oncol. 2009; 27(15S): 10502–10502.
    CrossRef
  63. Wagner AJ, Goldberg JM, Dubois SG, et al. Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial. Cancer. 2012; 118(23): 5894–5902.
    CrossRefPubMed
  64. Schöffski P, Wozniak A, Stacchiotti S, et al. Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'. Ann Oncol. 2017 [Epub ahead of print]; 28(12): 3000–3008.
    CrossRefPubMed
  65. Mir O, Boudou-Rouquette P, Larousserie F, et al. Objective response to sorafenib in advanced clear-cell sarcoma. Ann Oncol. 2012; 23(3): 807–809.
    CrossRefPubMed
  66. Stacchiotti S, Grosso F, Negri T, et al. Tumor response to sunitinib malate observed in clear-cell sarcoma. Ann Oncol. 2010; 21(5): 1130–1131.
    CrossRefPubMed
  67. Chi Y, Fang Z, Hong X, et al. Safety and efficacy of anlotinib, a multikinase angiogenesis inhibitor, in patients with refractory metastatic soft-tissue sarcoma. Clin Cancer Res. 2018 [Epub ahead of print].
    CrossRefPubMed
  68. Steger GG, Wrba F, Mader R, et al. Complete remission of metastasised clear cell sarcoma of tendons and aponeuroses. Eur J Cancer. 1991; 27(3): 254–256.
    PubMed
  69. Lauro S, Bordin F, Trasatti L, et al. Concurrent chemoimmunotherapy in metastatic clear cell sarcoma: a case report. Tumori. 1999; 85(6): 512–514.
    PubMed
  70. Marcrom S, De Los Santos JF, Conry RM. Complete response of mediastinal clear cell sarcoma to pembrolizumab with radiotherapy. Clin Sarcoma Res. 2017; 7: 14.
    CrossRefPubMed
  71. Scheinberg T, Lomax A, Tattersall M, et al. PD-1 blockade using pembrolizumab in adolescent and young adult patients with advanced bone and soft tissue sarcoma. J Clin Oncol. 2017; 35(Suppl 15): 3060.
    CrossRef
  72. Goldberg JM, Fisher DE, Demetri GD, et al. Biologic activity of autologous, granulocyte-macrophage colony-stimulating factor secreting alveolar soft-part sarcoma and clear cell sarcoma vaccines. Clin Cancer Res. 2015; 21(14): 3178–3186.
    CrossRefPubMed
  73. Tsukahara T, Emori M, Murata K, et al. The future of immunotherapy for sarcoma. Expert Opin Biol Ther. 2016; 16(8): 1049–1057.
    CrossRefPubMed
  74. Kuiper DR, Hoekstra HJ, Veth RPH, et al. The management of clear cell sarcoma. Eur J Surg Oncol. 2003; 29(7): 568–570.
    CrossRefPubMed
  75. Lewis JJ, Leung D, Heslin M, et al. Association of local recurrence with subsequent survival in extremity soft tissue sarcoma. J Clin Oncol. 1997; 15(2): 646–652.
    CrossRefPubMed
  76. Firmin N, Boudou-Rouquette P, Duliege D, et al. Outcome of 91 clear cell sarcoma tumor patients: A retrospective study from the French Sarcoma Group (GSF-GETO). J clin Oncol. 2018; 36(Suppl 15): 11552–11552.
    CrossRef
  77. Hong D, Rosen P, Lockhart A, et al. A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors. Oncotarget. 2015; 6(21): 18693–18706.
    CrossRef

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl